Dyax Corp.
(NASDAQ : DYAX)

( )
DYAX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 3.51%52.430.9%$1363.76m
JNJJohnson & Johnson 1.74%176.970.7%$1352.49m
BMYBristol-Myers Squibb Co. 0.36%76.231.0%$1197.90m
ABBVAbbVie, Inc. -0.53%150.921.9%$1137.44m
MRKMerck & Co., Inc. 1.26%93.250.7%$1136.00m
LLYEli Lilly & Co. 4.49%299.111.1%$892.99m
AZNAstraZeneca Plc 2.59%66.211.0%$517.65m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.65%141.960.0%$458.27m
VERUVeru, Inc. -6.37%13.380.0%$318.66m
NVSNovartis AG 0.86%89.410.2%$251.17m
GSKGlaxoSmithKline Plc 2.23%44.530.2%$243.21m
HZNPHorizon Therapeutics Plc 1.13%90.355.4%$200.40m
NVONovo Nordisk A/S 3.49%107.680.1%$190.60m
SGENSeagen Inc. -2.10%139.645.7%$181.75m
VTRSViatris, Inc. 0.94%11.800.0%$166.13m

Company Profile

Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company's lead product, DX-88, has been approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. The Company commercializes KALBITOR on its own in the United States. In addition to its approved commercial use for HAE in the United States, the Company is also developing DX-88 through collaborations in other indications. These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), which was acquired by sanofi-aventis during the year ended December 31, 2009.